Vivet Therapeutics presents interim data on its Phase 1/2 GATEWAY trial for the Treatment of Wilson Disease at EASL Congress 2024

VTX-801 increased ceruloplasmin ferroxidase activity and improved liver histology

Encouraging safety and tolerability with no serious adverse events reported

Paris, France, June 5, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces the presentation of interim data on its international Phase 1/2 GATEWAY trial, evaluating the safety, pharmacodynamics, and efficacy of its lead program, VTX-801 for the treatment of Wilson Disease (WD) at the EASL Congress 2024, held in Milan, Italy.

Read more…